Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Central GLP-1 effects on brain satiety and reward responses in obesity and type 2 diabetes
NL-OMON39550Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Oct 2011
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of liraglutide, exendin 9-39 and insulin glargine in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by Vrije University Medical Center. Primary endpoints: Endogenous GLP-1 effect on CNS satiety and reward circuitry, Difference between obese type 2 diabetes and lean healthy subjects in endogenous GLP-1 effect and 2 more. Started Oct 2011; status: active, not recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NL-OMON39550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39550.